22/42
2.6 / 5 stars
All 42 Win/Lose results and 78 gray no-data contests shown below
COGT Roast Me summary
Cogent Biosciences, Inc. (COGT). Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth No data.
- 2025-Q4: Total return Win; Revenue growth No data; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth No data.
Trailing 1 year (4 quarters): 3 wins, 1 losses, 8 no dataLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/1 |
LoseCOGT / S&P 0.55% / 15.20% |
No dataCOGT / S&P / 15.00% |
No dataCOGT / S&P / 50.40% |
| 2026-Q11/1 |
WinCOGT / S&P 8.36% / -4.33% |
No dataCOGT / S&P / 11.30% |
No dataCOGT / S&P / 27.70% |
| 2025-Q41/1 |
WinCOGT / S&P 147.35% / 2.65% |
No dataCOGT / S&P / 9.00% |
No dataCOGT / S&P / 13.40% |
| 2025-Q31/1 |
WinCOGT / S&P 100.00% / 8.12% |
No dataCOGT / S&P / 4.61% |
No dataCOGT / S&P / 13.45% |
| 2025-Q21/1 |
WinCOGT / S&P 19.87% / 10.94% |
No dataCOGT / S&P / 4.83% |
No dataCOGT / S&P / 10.63% |
| 2025-Q10/1 |
LoseCOGT / S&P -23.21% / -4.27% |
No dataCOGT / S&P / 4.98% |
No dataCOGT / S&P / 10.57% |
| 2024-Q40/1 |
LoseCOGT / S&P -27.78% / 2.41% |
No dataCOGT / S&P / 5.25% |
No dataCOGT / S&P / 6.15% |
| 2024-Q31/1 |
WinCOGT / S&P 28.11% / 5.89% |
No dataCOGT / S&P / 5.89% |
No dataCOGT / S&P / 6.11% |
| 2024-Q21/1 |
WinCOGT / S&P 25.45% / 4.28% |
No dataCOGT / S&P / 5.38% |
No dataCOGT / S&P / 5.12% |
| 2024-Q11/1 |
WinCOGT / S&P 14.29% / 10.56% |
No dataCOGT / S&P / 5.71% |
No dataCOGT / S&P / 5.59% |
| 2023-Q40/1 |
LoseCOGT / S&P -39.69% / 11.69% |
No dataCOGT / S&P / 6.81% |
No dataCOGT / S&P / 7.78% |
| 2023-Q30/1 |
LoseCOGT / S&P -17.65% / -3.27% |
No dataCOGT / S&P / 7.52% |
No dataCOGT / S&P / -5.03% |
| 2023-Q21/1 |
WinCOGT / S&P 9.73% / 8.74% |
No dataCOGT / S&P / 9.50% |
No dataCOGT / S&P / -8.57% |
| 2023-Q10/1 |
LoseCOGT / S&P -6.66% / 7.50% |
No dataCOGT / S&P / 10.77% |
No dataCOGT / S&P / -15.69% |
| 2022-Q40/1 |
LoseCOGT / S&P -22.52% / 7.56% |
No dataCOGT / S&P / 11.88% |
No dataCOGT / S&P / -17.99% |
| 2022-Q31/1 |
WinCOGT / S&P 65.41% / -4.88% |
No dataCOGT / S&P / 13.47% |
No dataCOGT / S&P / -1.41% |
| 2022-Q21/1 |
WinCOGT / S&P 20.43% / -16.10% |
No dataCOGT / S&P / 13.71% |
No dataCOGT / S&P / 11.04% |
| 2022-Q10/1 |
LoseCOGT / S&P -12.70% / -4.60% |
No dataCOGT / S&P / 15.97% |
No dataCOGT / S&P / 42.23% |
| 2021-Q40/1 |
LoseCOGT / S&P 2.02% / 11.03% |
No dataCOGT / S&P / 15.00% |
No dataCOGT / S&P / 96.40% |
| 2021-Q31/1 |
WinCOGT / S&P 3.70% / 0.58% |
No dataCOGT / S&P / 10.77% |
No dataCOGT / S&P / 69.42% |
| 2021-Q20/1 |
LoseCOGT / S&P -7.63% / 8.55% |
No dataCOGT / S&P / 6.58% |
No dataCOGT / S&P / 51.81% |
| 2021-Q10/1 |
LoseCOGT / S&P -21.82% / 6.17% |
No dataCOGT / S&P / -1.06% |
No dataCOGT / S&P / 7.39% |
| 2020-Q41/2 |
WinCOGT / S&P 19.98% / 12.15% |
LoseCOGT / S&P -65.02% / -3.72% |
No dataCOGT / S&P / -33.42% |
| 2020-Q32/2 |
WinCOGT / S&P 408.70% / 8.93% |
WinCOGT / S&P 110.23% / -2.04% |
No dataCOGT / S&P / -27.10% |
| 2020-Q21/2 |
LoseCOGT / S&P 11.38% / 20.54% |
WinCOGT / S&P 98.25% / -0.46% |
No dataCOGT / S&P / -27.11% |
| 2020-Q11/2 |
LoseCOGT / S&P -42.64% / -19.60% |
WinCOGT / S&P 150.56% / 3.47% |
No dataCOGT / S&P / -14.75% |
| 2019-Q41/2 |
LoseCOGT / S&P -50.00% / 9.07% |
WinCOGT / S&P 131.14% / 5.36% |
No dataCOGT / S&P / 2.99% |
| 2019-Q31/2 |
LoseCOGT / S&P -45.04% / 1.70% |
WinCOGT / S&P 36.81% / 5.02% |
No dataCOGT / S&P / 0.21% |
| 2019-Q21/2 |
LoseCOGT / S&P -40.32% / 4.30% |
WinCOGT / S&P 44.35% / 6.64% |
No dataCOGT / S&P / 8.65% |
| 2019-Q11/2 |
LoseCOGT / S&P -0.23% / 13.65% |
WinCOGT / S&P 20.72% / 8.12% |
No dataCOGT / S&P / 14.29% |
| 2018-Q41/2 |
LoseCOGT / S&P -57.28% / -13.52% |
WinCOGT / S&P 16.44% / 9.05% |
No dataCOGT / S&P / 18.23% |
| 2018-Q30/1 |
LoseCOGT / S&P -28.22% / 7.71% |
No dataCOGT / S&P / 10.21% |
No dataCOGT / S&P / 19.06% |
| 2018-Q21/1 |
WinCOGT / S&P 29.16% / 3.43% |
No dataCOGT / S&P / 9.03% |
No dataCOGT / S&P / 14.46% |
| 2018-Q10/0 |
No dataCOGT / S&P / -0.76% |
No dataCOGT / S&P / 7.68% |
No dataCOGT / S&P / 12.46% |
| 2017-Q40/0 |
No dataCOGT / S&P / 6.64% |
No dataCOGT / S&P / 7.03% |
No dataCOGT / S&P / 13.82% |
| 2017-Q30/0 |
No dataCOGT / S&P / 4.48% |
No dataCOGT / S&P / 5.68% |
No dataCOGT / S&P / 17.57% |
| 2017-Q20/0 |
No dataCOGT / S&P / 3.09% |
No dataCOGT / S&P / 4.83% |
No dataCOGT / S&P / 17.74% |
| 2017-Q10/0 |
No dataCOGT / S&P / 6.07% |
No dataCOGT / S&P / 3.67% |
No dataCOGT / S&P / 13.32% |
| 2016-Q40/0 |
No dataCOGT / S&P / 3.82% |
No dataCOGT / S&P / 2.09% |
No dataCOGT / S&P / 7.05% |
| 2016-Q30/0 |
No dataCOGT / S&P / 3.85% |
No dataCOGT / S&P / 0.20% |
No dataCOGT / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | COGT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 187.08% | 20.78% |
| Annualized return | 187.08% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | COGT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 311.38% | 83.14% |
| Annualized return | 32.69% | 12.86% |
10Y · 2018-03-29 to 2026-08-28
| Metric | COGT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -21.96% | 319.30% |
| Annualized return | -2.45% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |